Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2005-11-16 15:48:42 UTC |
---|
Update Date | 2022-03-07 02:49:07 UTC |
---|
HMDB ID | HMDB0000961 |
---|
Secondary Accession Numbers | - HMDB0004201
- HMDB00961
- HMDB04201
|
---|
Metabolite Identification |
---|
Common Name | Farnesyl pyrophosphate |
---|
Description | Farnesyl pyrophosphate, also known as farnesyl diphosphoric acid or farnesyl-PP, belongs to the class of organic compounds known as sesquiterpenoids. These are terpenes with three consecutive isoprene units. Farnesyl pyrophosphate is a very hydrophobic molecule, practically insoluble (in water), and relatively neutral. |
---|
Structure | [H]\C(CC\C(C)=C(/[H])COP(O)(=O)OP(O)(O)=O)=C(\C)CCC=C(C)C InChI=1S/C15H28O7P2/c1-13(2)7-5-8-14(3)9-6-10-15(4)11-12-21-24(19,20)22-23(16,17)18/h7,9,11H,5-6,8,10,12H2,1-4H3,(H,19,20)(H2,16,17,18)/b14-9+,15-11+ |
---|
Synonyms | Value | Source |
---|
(2E,6E)-Farnesol diphosphate | ChEBI | (2E,6E)-Farnesyl diphosphate | ChEBI | (2E,6E)-Farnesyl pyrophosphate | ChEBI | (all-e)-Farnesyl diphosphate | ChEBI | (e,e)-Farnesyl pyrophosphate | ChEBI | 2-trans,6-trans-Farnesyl pyrophosphate | ChEBI | all-trans-Farnesyl pyrophosphate | ChEBI | Farnesyl diphosphate | ChEBI | trans,trans-Farnesyl diphosphate | ChEBI | trans-trans-Farnesyl diphosphate | ChEBI | 2-trans,6-trans-Farnesyl diphosphate | Kegg | (2E,6E)-Farnesol diphosphoric acid | Generator | (2E,6E)-Farnesyl diphosphoric acid | Generator | (2E,6E)-Farnesyl pyrophosphoric acid | Generator | (all-e)-Farnesyl diphosphoric acid | Generator | (e,e)-Farnesyl pyrophosphoric acid | Generator | 2-trans,6-trans-Farnesyl pyrophosphoric acid | Generator | all-trans-Farnesyl pyrophosphoric acid | Generator | Farnesyl diphosphoric acid | Generator | trans,trans-Farnesyl diphosphoric acid | Generator | trans-trans-Farnesyl diphosphoric acid | Generator | 2-trans,6-trans-Farnesyl diphosphoric acid | Generator | Farnesyl pyrophosphoric acid | Generator | (e,e)-Farnesyl diphosphate | HMDB | Farnesyl-PP | HMDB | trans-Farnesyl pyrophosphate | HMDB | trans-trans-Farnesyl pyrophosphate | HMDB | Farnesyl pyrophosphate, (e,e)-isomer | HMDB | Farnesyl pyrophosphate, (e,Z)-isomer | HMDB | Farnesyl pyrophosphate, (Z,e)-isomer | HMDB | Farnesyl pyrophosphate, (Z,Z)-isomer | HMDB | Farnesylpyrophosphate | HMDB |
|
---|
Chemical Formula | C15H28O7P2 |
---|
Average Molecular Weight | 382.33 |
---|
Monoisotopic Molecular Weight | 382.131027238 |
---|
IUPAC Name | {[hydroxy({[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]oxy})phosphoryl]oxy}phosphonic acid |
---|
Traditional Name | farnesyl diphosphate |
---|
CAS Registry Number | 13058-04-3 |
---|
SMILES | CC(C)=CCC\C(C)=C\CC\C(C)=C\COP(O)(=O)OP(O)(O)=O |
---|
InChI Identifier | InChI=1S/C15H28O7P2/c1-13(2)7-5-8-14(3)9-6-10-15(4)11-12-21-24(19,20)22-23(16,17)18/h7,9,11H,5-6,8,10,12H2,1-4H3,(H,19,20)(H2,16,17,18)/b14-9+,15-11+ |
---|
InChI Key | VWFJDQUYCIWHTN-YFVJMOTDSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as sesquiterpenoids. These are terpenes with three consecutive isoprene units. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Prenol lipids |
---|
Sub Class | Sesquiterpenoids |
---|
Direct Parent | Sesquiterpenoids |
---|
Alternative Parents | |
---|
Substituents | - Farsesane sesquiterpenoid
- Sesquiterpenoid
- Organic pyrophosphate
- Isoprenoid phosphate
- Monoalkyl phosphate
- Alkyl phosphate
- Phosphoric acid ester
- Organic phosphoric acid derivative
- Organic oxygen compound
- Organic oxide
- Hydrocarbon derivative
- Organooxygen compound
- Aliphatic acyclic compound
|
---|
Molecular Framework | Aliphatic acyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Not Available | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times UnderivatizedChromatographic Method | Retention Time | Reference |
---|
Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 8.14 minutes | 32390414 | Predicted by Siyang on May 30, 2022 | 11.2194 minutes | 33406817 | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.37 minutes | 32390414 | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 214.9 seconds | 40023050 | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2108.1 seconds | 40023050 | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 182.3 seconds | 40023050 | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 139.3 seconds | 40023050 | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 167.5 seconds | 40023050 | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 83.9 seconds | 40023050 | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 472.4 seconds | 40023050 | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 599.7 seconds | 40023050 | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 114.0 seconds | 40023050 | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 867.2 seconds | 40023050 | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 527.0 seconds | 40023050 | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 538.9 seconds | 40023050 | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 355.7 seconds | 40023050 | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 279.6 seconds | 40023050 | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 471.8 seconds | 40023050 | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 208.5 seconds | 40023050 | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 33.3 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Farnesyl pyrophosphate,1TMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O[Si](C)(C)C)OP(=O)(O)O | 2733.9 | Semi standard non polar | 33892256 | Farnesyl pyrophosphate,1TMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O[Si](C)(C)C)OP(=O)(O)O | 2329.2 | Standard non polar | 33892256 | Farnesyl pyrophosphate,1TMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O[Si](C)(C)C)OP(=O)(O)O | 3598.0 | Standard polar | 33892256 | Farnesyl pyrophosphate,1TMS,isomer #2 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O)OP(=O)(O)O[Si](C)(C)C | 2724.8 | Semi standard non polar | 33892256 | Farnesyl pyrophosphate,1TMS,isomer #2 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O)OP(=O)(O)O[Si](C)(C)C | 2332.2 | Standard non polar | 33892256 | Farnesyl pyrophosphate,1TMS,isomer #2 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O)OP(=O)(O)O[Si](C)(C)C | 3630.0 | Standard polar | 33892256 | Farnesyl pyrophosphate,2TMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O[Si](C)(C)C)OP(=O)(O)O[Si](C)(C)C | 2738.4 | Semi standard non polar | 33892256 | Farnesyl pyrophosphate,2TMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O[Si](C)(C)C)OP(=O)(O)O[Si](C)(C)C | 2395.4 | Standard non polar | 33892256 | Farnesyl pyrophosphate,2TMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O[Si](C)(C)C)OP(=O)(O)O[Si](C)(C)C | 3235.9 | Standard polar | 33892256 | Farnesyl pyrophosphate,2TMS,isomer #2 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O)OP(=O)(O[Si](C)(C)C)O[Si](C)(C)C | 2739.1 | Semi standard non polar | 33892256 | Farnesyl pyrophosphate,2TMS,isomer #2 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O)OP(=O)(O[Si](C)(C)C)O[Si](C)(C)C | 2379.3 | Standard non polar | 33892256 | Farnesyl pyrophosphate,2TMS,isomer #2 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O)OP(=O)(O[Si](C)(C)C)O[Si](C)(C)C | 3235.6 | Standard polar | 33892256 | Farnesyl pyrophosphate,3TMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O[Si](C)(C)C)OP(=O)(O[Si](C)(C)C)O[Si](C)(C)C | 2746.2 | Semi standard non polar | 33892256 | Farnesyl pyrophosphate,3TMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O[Si](C)(C)C)OP(=O)(O[Si](C)(C)C)O[Si](C)(C)C | 2465.7 | Standard non polar | 33892256 | Farnesyl pyrophosphate,3TMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O[Si](C)(C)C)OP(=O)(O[Si](C)(C)C)O[Si](C)(C)C | 2863.8 | Standard polar | 33892256 | Farnesyl pyrophosphate,1TBDMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O[Si](C)(C)C(C)(C)C)OP(=O)(O)O | 2952.4 | Semi standard non polar | 33892256 | Farnesyl pyrophosphate,1TBDMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O[Si](C)(C)C(C)(C)C)OP(=O)(O)O | 2486.4 | Standard non polar | 33892256 | Farnesyl pyrophosphate,1TBDMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O[Si](C)(C)C(C)(C)C)OP(=O)(O)O | 3719.4 | Standard polar | 33892256 | Farnesyl pyrophosphate,1TBDMS,isomer #2 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O)OP(=O)(O)O[Si](C)(C)C(C)(C)C | 2941.7 | Semi standard non polar | 33892256 | Farnesyl pyrophosphate,1TBDMS,isomer #2 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O)OP(=O)(O)O[Si](C)(C)C(C)(C)C | 2506.6 | Standard non polar | 33892256 | Farnesyl pyrophosphate,1TBDMS,isomer #2 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O)OP(=O)(O)O[Si](C)(C)C(C)(C)C | 3747.7 | Standard polar | 33892256 | Farnesyl pyrophosphate,2TBDMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O[Si](C)(C)C(C)(C)C)OP(=O)(O)O[Si](C)(C)C(C)(C)C | 3128.2 | Semi standard non polar | 33892256 | Farnesyl pyrophosphate,2TBDMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O[Si](C)(C)C(C)(C)C)OP(=O)(O)O[Si](C)(C)C(C)(C)C | 2709.6 | Standard non polar | 33892256 | Farnesyl pyrophosphate,2TBDMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O[Si](C)(C)C(C)(C)C)OP(=O)(O)O[Si](C)(C)C(C)(C)C | 3378.4 | Standard polar | 33892256 | Farnesyl pyrophosphate,2TBDMS,isomer #2 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O)OP(=O)(O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3138.3 | Semi standard non polar | 33892256 | Farnesyl pyrophosphate,2TBDMS,isomer #2 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O)OP(=O)(O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 2671.2 | Standard non polar | 33892256 | Farnesyl pyrophosphate,2TBDMS,isomer #2 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O)OP(=O)(O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3398.4 | Standard polar | 33892256 | Farnesyl pyrophosphate,3TBDMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O[Si](C)(C)C(C)(C)C)OP(=O)(O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3299.3 | Semi standard non polar | 33892256 | Farnesyl pyrophosphate,3TBDMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O[Si](C)(C)C(C)(C)C)OP(=O)(O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 2890.4 | Standard non polar | 33892256 | Farnesyl pyrophosphate,3TBDMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O[Si](C)(C)C(C)(C)C)OP(=O)(O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3094.2 | Standard polar | 33892256 |
|
---|
General References | - Notarnicola M, Messa C, Cavallini A, Bifulco M, Tecce MF, Eletto D, Di Leo A, Montemurro S, Laezza C, Caruso MG: Higher farnesyl diphosphate synthase activity in human colorectal cancer inhibition of cellular apoptosis. Oncology. 2004;67(5-6):351-8. [PubMed:15713990 ]
- Shellman YG, Ribble D, Miller L, Gendall J, Vanbuskirk K, Kelly D, Norris DA, Dellavalle RP: Lovastatin-induced apoptosis in human melanoma cell lines. Melanoma Res. 2005 Apr;15(2):83-9. [PubMed:15846140 ]
- Argmann CA, Edwards JY, Sawyez CG, O'Neil CH, Hegele RA, Pickering JG, Huff MW: Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux. J Biol Chem. 2005 Jun 10;280(23):22212-21. Epub 2005 Apr 6. [PubMed:15817453 ]
- Reigard SA, Zahn TJ, Haworth KB, Hicks KA, Fierke CA, Gibbs RA: Interplay of isoprenoid and peptide substrate specificity in protein farnesyltransferase. Biochemistry. 2005 Aug 23;44(33):11214-23. [PubMed:16101305 ]
- Tacer KF, Haugen TB, Baltsen M, Debeljak N, Rozman D: Tissue-specific transcriptional regulation of the cholesterol biosynthetic pathway leads to accumulation of testis meiosis-activating sterol (T-MAS). J Lipid Res. 2002 Jan;43(1):82-9. [PubMed:11792726 ]
- Saisho Y, Morimoto A, Umeda T: Determination of farnesyl pyrophosphate in dog and human plasma by high-performance liquid chromatography with fluorescence detection. Anal Biochem. 1997 Oct 1;252(1):89-95. [PubMed:9324945 ]
- Sanders JM, Song Y, Chan JM, Zhang Y, Jennings S, Kosztowski T, Odeh S, Flessner R, Schwerdtfeger C, Kotsikorou E, Meints GA, Gomez AO, Gonzalez-Pacanowska D, Raker AM, Wang H, van Beek ER, Papapoulos SE, Morita CT, Oldfield E: Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption. J Med Chem. 2005 Apr 21;48(8):2957-63. [PubMed:15828834 ]
- Fukuchi J, Song C, Ko AL, Liao S: Transcriptional regulation of farnesyl pyrophosphate synthase by liver X receptors. Steroids. 2003 Sep;68(7-8):685-91. [PubMed:12957674 ]
|
---|